O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

Detalles Bibliográficos
Autores principales: A., SILVA-PINTO, R., COLOMBATTI, A., PASANISI, F., ARCIONI, L., DEBONNETT, W., SOLIMAN, R., SARKAR, R., CANÇADO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426842/
http://dx.doi.org/10.1097/01.HS9.0000872824.25632.d4
_version_ 1784778769425235968
author A., SILVA-PINTO
R., COLOMBATTI
A., PASANISI
F., ARCIONI
L., DEBONNETT
W., SOLIMAN
R., SARKAR
R., CANÇADO
author_facet A., SILVA-PINTO
R., COLOMBATTI
A., PASANISI
F., ARCIONI
L., DEBONNETT
W., SOLIMAN
R., SARKAR
R., CANÇADO
author_sort A., SILVA-PINTO
collection PubMed
description
format Online
Article
Text
id pubmed-9426842
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94268422022-08-31 O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP) A., SILVA-PINTO R., COLOMBATTI A., PASANISI F., ARCIONI L., DEBONNETT W., SOLIMAN R., SARKAR R., CANÇADO Hemasphere Oral Presentations Lippincott Williams & Wilkins 2022-08-16 /pmc/articles/PMC9426842/ http://dx.doi.org/10.1097/01.HS9.0000872824.25632.d4 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Presentations
A., SILVA-PINTO
R., COLOMBATTI
A., PASANISI
F., ARCIONI
L., DEBONNETT
W., SOLIMAN
R., SARKAR
R., CANÇADO
O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_full O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_fullStr O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_full_unstemmed O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_short O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_sort o-04: incidence of vaso-occlusive crises in patients with sickle cell disease (scd) and a high baseline disease burden treated with crizanlizumab in a real-world setting: results from a managed access program (map)
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426842/
http://dx.doi.org/10.1097/01.HS9.0000872824.25632.d4
work_keys_str_mv AT asilvapinto o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap
AT rcolombatti o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap
AT apasanisi o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap
AT farcioni o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap
AT ldebonnett o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap
AT wsoliman o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap
AT rsarkar o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap
AT rcancado o04incidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabinarealworldsettingresultsfromamanagedaccessprogrammap

Ejemplares similares